ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.72B +30.9% |
| Revenue (ttm) | 923.71M +37.0% |
| Net Income | 83.94M |
| EPS | 3.90 |
| Shares Out | 21.20M |
| PE Ratio | 20.78 |
| Forward PE | 8.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 338,183 |
| Open | 79.77 |
| Previous Close | 79.20 |
| Day's Range | 79.25 - 81.31 |
| 52-Week Range | 59.61 - 99.50 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 109.88 (+35.47%) |
| Earnings Date | May 8, 2026 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price target is $109.88, which is an increase of 35.47% from the latest price.
News
ANI Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Management outlined a strategy focused on rare disease growth, with Cortrophin Gel and ILUVIEN as key assets and a major sales force expansion targeting under-penetrated markets. Strong momentum is expected to drive a significant second-half sales ramp, while a new licensing deal adds royalty potential.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fire...
ANI Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and stock plan approval. All proposals passed, including annual advisory votes on compensation. No shareholder questions were raised during the session.
ANI Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% revenue growth and 24% adjusted EBITDA growth, driven by Rare Disease and Generics, with Cortrophin Gel revenues up 42% year-over-year. 2026 guidance was raised, and a $100M share repurchase program was announced.
ANI Pharmaceuticals Earnings release: Q1 2026
ANI Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
ANI Pharmaceuticals Quarterly report: Q1 2026
ANI Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
ANI Pharmaceuticals Slides: Q1 2026
ANI Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
Reports Q1 revenue $237.46M, consensus $207.63M. “We delivered a strong first quarter, generating $237.5M in revenue and $63.0M in adjusted non-GAAP EBITDA, with solid performance across all business ...
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended Ma...
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results...
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
ANI Pharmaceuticals (ANIP) announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug Orap. U.S. annual sales…
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets i...
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg ...
ANI Pharmaceuticals Proxy statement: Proxy filing
ANI Pharmaceuticals filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ANI Pharmaceuticals Proxy statement: Proxy filing
ANI Pharmaceuticals filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, or ANDA, the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20…
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administrati...
ANI Pharmaceuticals announces publication of iluvien clinical trial results
ANI Pharmaceuticals (ANIP) announced publication of the results from the NEW DAY clinical trial involving iluvien – fluocinolone acetonide intravitreal implant -, 0.19 mg for use in appropriate patien...
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving I...
ANI Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Rare Disease assets now drive 60% of revenue, with Cortrophin and ILUVIEN showing strong growth and long-term durability due to large underpenetrated markets and patent protection. Generics and Brands provide cash flow for reinvestment, while expanded sales teams and strategic initiatives support continued momentum.
ANI Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Strong 2025 results and robust 2026 guidance highlight rare disease as the main growth driver, with Cortrophin Gel expansion and a new sales force targeting acute gouty arthritis. ILUVIEN's growth is supported by new data and label expansion, while operating leverage is expected in 2027.
ANI Pharmaceuticals Transcript: 47th Annual Raymond James Institutional Investor Conference
The company projects over $1 billion in 2026 sales, driven by rare disease growth and strong Generics cash flow. Cortrophin Gel and ILUVIEN are key assets, with new commercial initiatives and clinical investments targeting under-penetrated markets.
ANI Pharmaceuticals Slides: Corporate presentation
ANI Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
ANI Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 results with 44% revenue growth and 47% adjusted EBITDA growth, led by rare disease and generics. 2026 guidance targets over $1B in revenue, with Cortrophin Gel and generics as key drivers and significant investments in sales force expansion and clinical evidence generation.
ANI Pharmaceuticals Annual report: Q4 2025
ANI Pharmaceuticals has published its Q4 2025 annual report on February 27, 2026.